<DOC>
	<DOCNO>NCT01036659</DOCNO>
	<brief_summary>The investigator conduct double-blind , randomize control trial compare safety effectiveness ecallantide conventional therapy . A rescue cross-over design use patient fail improve standard therapy additionally treat ecallantide . Therefore , historical control cohort enrol analysis secondary endpoint . In addition , since patient treated conventional therapy may improve rapidly therefore eligible inclusion study , investigator enroll patient observational arm enable conduct sensitivity analysis .</brief_summary>
	<brief_title>Evaluation Ecallantide Acute Treatment Angiotensin Converting Enzyme Inhibitor Induced Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<criteria>1 . Males females race ethnicity 18 older . The location study permit racial ethnic distribution study 2 . Must currently ACE inhibitor 3 . Presenting ACE induce angioedema within 12 hour onset . This document source document CRF 4 . All female childbearing age must negative pregnancy test prior administration study drug . 1 . Participation another investigational study within 30 day prior enrollment 2 . Patients improve conventional ( standard care ) therapy 3 . Patients previously treat ecallantide 4 . Hypersensitivity ecallantide 5 . Pregnancy breast feed 6 . Other definable cause angioedema ( i.e. , hereditary acquire angioedema ) 7 . Patients receive C1 inhibitor prophylaxis 8 . Treatment require tranexamic acid , epsilonaminocaproic acid 9 . Receiving fresh frozen plasma within 3 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>acute angiotensin convert enzyme inhibitor angioedema</keyword>
</DOC>